What are challenges in development of novel drug delivery system?
Answers from top 2 papers
More filters
| Papers (2) | Insight |
|---|---|
32 Citations | The encouragement in development of novel drug delivery system is apart from therapeutic efficacy is its cause. |
| This work may provide a new modality for developing an effective drug delivery system. |
Related Questions
What are challenges for liposome delivery system?5 answersChallenges for liposome delivery systems include overcoming harsh gastrointestinal conditions, limited permeability across intestinal epithelia, instability of traditional Chinese herbal components, and low bioavailability of decoctions. Additionally, challenges arise in designing liposomal systems for food and nutraceuticals due to the acidic stomach environment, formulation complexities, and the need for effective encapsulation while maintaining bioavailability. Despite these obstacles, liposomes offer benefits such as high biocompatibility, improved solubility, enhanced drug stability, and reduced side effects, making them a promising drug delivery system for various applications in pharmaceuticals, food, and nutraceutical industries. Efforts to modify and strengthen liposomes aim to enhance their stability, permeability, and targetability for more effective and efficient delivery of therapeutic agents.
What are the current advancements and challenges in the development of polymeric carriers for drug delivery?5 answersPolymeric carriers for drug delivery have seen advancements and challenges in their development. Stimulus-responsive polymeric vectors, such as pH, redox, or enzyme-responsive systems, have been explored for controllable delivery of CRISPR/Cas9 genome editing systems and cancer treatment. Polymer therapeutics have enabled the creation of unique materials and combination with bioactive agents, improving drug therapy. Polymeric nano-based drug delivery systems have shown promise in overcoming barriers in ocular drug delivery, offering higher bioavailability and longer residence time. Superabsorbent polymers (SAPs) have been investigated as drug carriers due to their ability to absorb and release drugs in a controlled manner. Dendritic polymers, with their unique properties and multiple surface functionalities, have been utilized as drug delivery carriers, although their toxicity remains a challenge. These advancements in polymeric carriers offer opportunities for improved drug delivery, but further research is needed to address challenges such as toxicity and targeted delivery.
What are the challenges in hydrogel based transdermal drug delivery?5 answersHydrogel-based transdermal drug delivery faces several challenges. One challenge is the translation to clinical application, which still has more obstacles to overcome. Another challenge is the management of the structure of stimuli-responsive hydrogels, which may require additional crosslinking agents. Additionally, the design and application of hydrogels for transdermal drug delivery need to consider unique considerations and challenges, such as the need for desirable mechanical properties and tunability of structure. These challenges highlight the need for further research and development in the field of hydrogel-based transdermal drug delivery systems.
What are the challenges in developing in situ ophthalmic drug delivery systems?5 answersDeveloping in situ ophthalmic drug delivery systems faces several challenges. The presence of ocular barriers and clearance mechanisms makes it difficult to safely and effectively deliver drugs to the eye. The anatomical and physiological barriers within the eyeball further complicate drug delivery. Conventional dosage forms, such as eye drops, are associated with rapid precorneal drug loss, leading to lower bioavailability. To overcome these challenges, researchers have been exploring novel drug delivery systems, including microneedle-based ocular patches, nanotechnology-based formulations, and iontophoresis techniques. These innovative approaches aim to enhance drug penetration, increase drug concentration, and improve bioavailability in targeted ocular tissues. However, there are still potential challenges and drawbacks to consider, such as patient tolerance and the unique anatomy and physiology of the eye. Overall, the development of in situ ophthalmic drug delivery systems requires addressing these challenges to ensure safe and effective treatment of ocular diseases.
What are the challenges in using carbon based nanomaterials for drug delivery?5 answersCarbon-based nanomaterials face several challenges in drug delivery. One of the common drawbacks is low drug loading and high initial burst release. Additionally, there are concerns regarding the toxicity of carbon nanomaterials and their interactions with cells. Another challenge is the need for advanced methods of surface functionalization to improve the utilization of carbonaceous nanocomposites. Furthermore, the full utilization of carbonaceous nanocomposites is still a challenge that needs to be addressed. Despite these challenges, carbon-based nanomaterials offer advantages such as low toxicity, high bioavailability, and perfect performances, making them promising candidates for drug delivery systems. Overall, further research and development are needed to overcome these challenges and fully harness the potential of carbon-based nanomaterials in drug delivery applications.
What are the challenges found in the development of new fixed-dose combination drugs in the form of tablets?3 answersThe challenges in the development of new fixed-dose combination drugs in tablet form include patient compliance issues due to differences in dose frequencies and dosage regimens for different conditions. Additionally, the differences in individual drug characteristics, drug release profiles, therapeutic dose, and solubility need to be considered for the design and formulation of fixed-dose combinations. Biopharmaceutical issues associated with drug combinations also need to be addressed, and multidrug eutectics have shown promise in improving the biopharmaceutical attributes of combination therapies. Furthermore, when developing fixed-dose combination tablets, it is important to assess the pharmacokinetic profile of the combination compared to its individual components to ensure therapeutic efficacy and improve patient compliance. Overall, the development of fixed-dose combination tablets requires careful consideration of dose flexibility, drug interactions, and the physicochemical properties of the drugs involved.